{"id":"W3174572714","doi":"10.1158/1538-7445.am2021-ct207","title":"Abstract CT207: Phase 1 first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumors","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Common Terminology Criteria for Adverse Events; Tolerability; Oncology; Adverse effect; Internal medicine; Response Evaluation Criteria in Solid Tumors; Clinical trial; Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001120257,0.00172702,0.002238266,0.000537304,0.000499471,0.00126896,0.0009266744,0.00121937,0.004621125],"category_scores_gemma":[0.0007926985,0.0006452503,0.001067662,0.0004642566,0.001096073,0.0007405038,0.0003101995,0.003053904,0.001380889],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001296278,"about_ca_system_score_gemma":0.002270199,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001712326,"about_ca_topic_score_gemma":0.004701473,"domain_scores_codex":[0.9996087,0.0001960912,0.00001695005,0.00004937033,0.00003712758,0.00009176983],"domain_scores_gemma":[0.9995352,0.00006859864,0.00006746417,0.00003089796,0.00003335479,0.0002645222],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6552612,0.09941661,0.007531925,0.001711372,0.001503423,0.0008674629,0.0004429785,0.005135949,0.1137127,0.0008279963,0.01513483,0.0984536],"study_design_scores_gemma":[0.3969348,0.5795134,0.007521219,0.00005658006,0.0004506061,0.0005402897,0.0000929778,0.0017359,0.008007674,0.0002362914,0.004863463,0.00004677933],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854939,0.00252442,0.0008127998,0.0007206417,0.0001996235,0.004615939,0.002155598,0.0002586228,0.003218475],"genre_scores_gemma":[0.9824567,0.001835337,0.002234251,0.001184544,0.0002116009,0.004183731,0.003313449,0.00006037796,0.004520074],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004621125,"threshold_uncertainty_score":0.01545918,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0641380885522939,"score_gpt":0.4456831917531299,"score_spread":0.381545103200836,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}